<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02834884</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-1553</org_study_id>
    <nct_id>NCT02834884</nct_id>
  </id_info>
  <brief_title>SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access</brief_title>
  <acronym>SPECTA</acronym>
  <official_title>SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      SPECTA is a program aiming at establishing a quality assured platform for collecting
      clinicopathologically annotated biological material, imaging data, as well as
      patient-reported outcomes from cancer patients to support biospecimen-based translational
      research and biomarker discovery to improve the understanding of tumor biology and cancer
      patients care.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 3, 2017</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Number of enrolled patients per year with adequate clinicopathologically annotated biological material and clinical data.</measure>
    <time_frame>5 years</time_frame>
    <description>The SPECTA program will establish a quality assured platform for collecting clinicopathologically annotated biological material (including imaging data) as well as patient-reported outcomes from patients with cancer diagnosis to support biospecimen-based translational research and biomarker discovery to improve the understanding of tumor biology and cancer patients care.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of downstream clinical trials</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients enrolled in downstream clinical trials</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For each molecular test: number of patients with a test result</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of research projects performed and published</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>All Tumor Types</condition>
  <arm_group>
    <arm_group_label>all tumor types</arm_group_label>
    <description>Pathologically confirmed selected tumor types, including rare tumors. The SPECTA Steering Committee will decide on project basis which tumor types and stages to include at any particular time during the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Biomarker assessment</intervention_name>
    <description>Predictive and prognostic biomarker assessment</description>
    <arm_group_label>all tumor types</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>NGS, IHC</intervention_name>
    <description>Diagnostic tests to check eligibility for a specific targeted trial</description>
    <arm_group_label>all tumor types</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      FFPE tissue sample; Blood sample; Fresh bone marrow sample (in case of hematological
      malignancies)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with pathologically confirmed selected tumor types.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        -  Patients with pathologically confirmed selected tumor types;

          -  Mandatory availability of adequate human biological material (HBM): at least one FFPE
             tissue sample or fresh bone marrow sample in the case of hematological malignancies,
             from either the primary tumor and/or recurrent tumor and/or metastasis, obtained from
             any adequate surgery or biopsy, as well as blood sample at baseline and follow up;

          -  Centrally performed confirmation of tumor tissue adequacy in terms of quality/
             quantity for central screening;

          -  Absence of any psychological, familial, sociological or geographical condition
             potentially hampering compliance with the study protocol and follow-up schedule;

          -  Age â‰¥ 12 years;

          -  Written informed consent according to applicable legal and ethical requirements;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vassilis Golfinopoulos, Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>European Organisation for Research and Treatment of Cancer - EORTC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lieve Dirix, PhD</last_name>
    <phone>+32 2 774 1567</phone>
    <email>lieve.dirix@eortc.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Katrien Baus</last_name>
    <phone>+32 2 774 1053</phone>
    <email>katrien.baus@eortc.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ZNA Middelheim</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Natacha Stern, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Emilie Le Rhun, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Assitance Publique - Hopitaux de Paris - Hopital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Patricia Pautier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maria Sklodowska-Curie Memorial Cancer Centre</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2016</study_first_submitted>
  <study_first_submitted_qc>July 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2016</study_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rare cancer</keyword>
  <keyword>biomarker</keyword>
  <keyword>molecular screening</keyword>
  <keyword>cancer</keyword>
  <keyword>biobanking</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

